Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: November 2011
-
By Donald Zuhn — The U.S. Patent and Trademark Office recently released its Performance and Accountability Report for Fiscal Year (FY) 2011. With respect to the Office's performance goals, the report indicates that four of five patent-related performance targets were met in FY 2011. Among the patent-related performance targets that the Office met were patent…
-
By Kevin E. Noonan — It is widely appreciated that the Supreme Court has spent the better part of the last ten years exercising its supervisory role over the Federal Circuit, something the Court generally refrained from doing for the first 15-20 years of the appellate court's existence (see "Is It Time for the Supreme…
-
By Kevin E. Noonan — A decade after completion of the Human Genome Project, and after more than a decade of hyperbole regarding the promise and benefits of "personalized medicine," genetic diagnostic testing has come to the attention of Congress. For example, Representative Debbie Wasserman Schultz (D-FL) introduced a provision of the Leahy-Smith America Invents…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Medicines Co. v. Sun Pharma Global FZE et al.2:11-cv-15175; filed November 23, 2011 in the Eastern District of Michigan • Plaintiff: Medicines Co.• Defendants: Sun Pharma Global FZE; Sun Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries…
-
November 30 to December 1, 2011 – Advanced Forum on Biotech Patents*** (American Conference Institute) – Boston, MA December 1, 2011 – Biotechnology/Chemical/ Pharmaceutical (BCP) Customer Partnership Meeting (U.S. Patent and Trademark Office) – 9:00 am – 5:15 pm (ET) December 1, 2011 – Strategic Implications of the Patent Reform Act of 2011 (American Bar…
-
American Conference Institute (ACI) a conference on Patent Reform for Life Sciences Companies from January 31 to February 1, 2012 in New York, NY. Topics of discussion at the conference will include: • Scrutinizing the specific provisions of patent reform in The America Invents Act (S. 23 & H.R. 1249);• Analyzing the impact of a…
-
The American Bar Association Section of Litigation and Navigant will be holding a IP legal roundtable on the "Strategic Implications of the Patent Reform Act of 2011" on December 1, 2011 from 12:00 to 1:30 pm at Navigant's offices in Chicago, IL. The roundtable will be moderated by Benjamin Bradford of Jenner & Block LLP. …
-
The authors and contributors of Patent Docs wish their readers and families a Happy Thanksgiving. Publication of Patent Docs will resume on November 25th.
-
By James DeGiulio — Pfizer Settles Lipitor Patent Suits with Aurobindo, Kremers Pfizer has settled separate cases with Aurobindo and Kremers, ending its patent infringement actions over the generic companies' efforts to enter the market for the cholesterol drug Lipitor. On June 27, 2011, Pfizer sued Aurobindo in response to the generic's filing of an…
-
By Kevin E. Noonan — Sometimes the U.S. and Europe seem to be on diametrically opposed trajectories when it comes to patent policy. One such moment was in the 1980's, when the U.S. Patent and Trademark Office responded to the Supreme Court's Diamond v. Chakrabarty decision by permitting broad patenting of biotechnological inventions while Europeans…
Patent Docs 